The effects of nicotine and cigarette smoke on the monoamine transporters

Synapse

Volumn 65, Issue 9, 2011, Pages 866-879

  Danielson, Kirsty ^a   Truman, Penelope ^b   Kivell, Bronwyn M ^a  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b INSTITUTE OF ENVIRONMENTAL SCIENCE AND RESEARCH   (New Zealand)

Author keywords

Addiction; Dopamine transporter; Norepinephrine transporter; Serotonin transporter

Indexed keywords

AMFEBUTAMONE; CHLORISONDAMINE; CIGARETTE SMOKE; CYCLIC AMP; CYCLOHEXIMIDE; DACTINOMYCIN; DOPAMINE TRANSPORTER; HEXAMETHONIUM; MECAMYLAMINE; METHYLLYCACONITINE; NICOTINE; NORADRENALIN TRANSPORTER; NORTRIPTYLINE; REBOXETINE; SEROTONIN TRANSPORTER;

ARTICLE; BINDING KINETICS; BIOTINYLATION; CALCIUM TRANSPORT; CELL SURFACE; CIGARETTE SMOKING; DOPAMINE UPTAKE; DOSE RESPONSE; DOWNSTREAM PROCESSING; DRUG DEPENDENCE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; NEUROTRANSMISSION; NONHUMAN; NORADRENALIN UPTAKE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RACE DIFFERENCE; RECEPTOR DENSITY; REGULATORY MECHANISM; SEROTONIN UPTAKE; SMOKING; SMOKING CESSATION; SYNAPTOSOME; WITHDRAWAL SYNDROME;

ANIMALS; BRAIN; GENE EXPRESSION REGULATION; HUMANS; NEUROTRANSMITTER TRANSPORT PROTEINS; NICOTINE; NICOTINIC AGONISTS; RATS; RECEPTORS, NICOTINIC; SMOKING; SMOKING CESSATION;

EID: 79959991689     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20914     Document Type: Article

References (106)

1. Ambrose V, Miller JH, Dickson SJ, Hampton S, Truman P, Lea RA, Fowles J. 2007. Tobacco particulate matter is more potent than nicotine at upregulating nicotinic receptors on SH-SY5Y cells. Nicotine Tobacco Res 9: 793-799.
2. Andreasen JT, Nielsen EO, Redrobe JP. 2009. Chronic oral nicotine increases brain [H-3]epibatidine binding and responsiveness to antidepressant drugs, but not nicotine, in the mouse forced swim test. Psychopharmacology 205: 517-528.
3. Apparsundaram S, Sung UH, Price RD, Blakely RD. 2001. Trafficking-dependent and -independent pathways of neurotransmitter transporter regulation differentially involving p38 mitogen-activated protein kinase revealed in studies of insulin modulation of norepinephrine transport in SK-N-SH cells. J Pharmacol Exp Therapeutics 299: 666-677.
4. Arib O, Rat P, Molimard R, Chait A, Faure P, de Beaurepaire R. 2010. Electrophysiological characterization of harmane-induced activation of mesolimbic dopamine neurons. Eur J Pharmacol 629(1-3): 47-52.
5. Awtry TL, Frank JG, Werling LL. 2006. In vitro regulation of serotonin transporter activity by protein kinase A and nicotinic acetylcholine receptors in the prefrontal cortex of rats. Synapse 59: 342-349.
6. Awtry TL, Werling LL. 2003. Acute and chronic effects of nicotine on serotonin uptake in prefrontal cortex and hippocampus of rats. Synapse 50: 206-211.
7. Balfour D, Benowitz N, Fagerstrom K, Kunze M, Keil U. 2000. Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy-A status report. Eur Heart J 21: 438-445.
8. Balfour DJK. 2002. The neurobiology of tobacco dependence: A commentary. Respiration 69: 7-11.
9. Bardo MT, Green TA, Crooks PA, Dwoskin LP. 1999. Nornicotine is self-administered intravenously by rats. Psychopharmacology 146: 290-296.
10. Benowitz NL. 1995. Acute biological effects of nicotine and its metabolites. In: Clarke PBS, Quik M, Adlkofer F, Thurau K, editors. Effects of nicotine on biological systems Ii. p 9-16.
11. Blakely RD, Defelice LJ, Hartzell HC. 1994. Molecular physiology of norepinephrine and serotonin transporters. J Exp Biol 196: 263-281.
12. Blondal T, Gudmundsson LJ, Tomasson K, Jonsdottir D, Hilmarsdottir H, Kristjansson F, Nilsson F, Bjornsdottir US. 1999. The effects of fluoxetine combined with nicotine inhalers in smoking cessation-A randomized trial. Addiction 94: 1007-1015.
13. Bolan EA, Kivell B, Jaligam V, Oz M, Jayanthi LD, Han Y, Sen N, Urizar E, Gomes I, Devi LA, Ramamoorthy S, Javitch JA, Zapata A, Shippenberg TS. 2007. D-2 receptors regulate dopamine transporter function via an extracellular signal-regulated kinases 1 and 2-dependent and phosphoinositide 3 kinase-independent mechanism. Mol Pharmacol 71: 1222-1232.
14. Bortolato M, Chen K, Shih JC. 2008. Monoamine oxidase inactivation: From pathophysiology to therapeutics. Adv Drug Deliv Rev 60(13-14): 1527-1533.
15. Butler SG, Meegan MJ. 2008. Recent developments in the design of anti-depressive therapies: Targeting the serotonin transporter. Current Med Chem 15: 1737-1761.
16. Christman AK, Fermo JD, Markowitz JS. 2004. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy 24: 1020-1036.
17. Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, Miller GW, Mufson EJ, Mash DC, Levey AI. 1999. Immunocytochemical localization of the dopamine transporter in human brain. J Compar Neurol 409: 38-56.
18. Clarke H, Flint J, Attwood AS, Munafo MR. 2010. Association of the 5-HTTLPR genotype and unipolar depression: A meta-analysis. Psychological Med 40: 1767-1778.
19. Clemens KJ, Caille S, Stinus L, Cador M. 2009. The addition of five minor tobacco alkaloids increases nicotine-induced hyperactivity, sensitization and intravenous self-administration in rats. Int J Neuropsychopharmacol 12: 1355-1366.
20. Coe JW, Brooks PR, Vetelino MG, Wirtz MC, Arnold EP, Huang JH, Sands SB, Davis TI, Lebel LA, Fox CB, Shrikhande A, Heym JH, Schaeffer E, Rollema H, Lu Y, Mansbach RS, Chambers LK, Rovetti CC, Schulz DW, Tingley FD, O'Neill BT. 2005. Varenicline: An alpha 4 beta 2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 48: 3474-3477.
21. Cordeiro Q, Siqueira-Roberto J, Vallada H. 2010. Association between the SLC6A3 A1343G polymorphism and schizophrenia. Arquivos De Neuro-Psiquiatria 68: 716-719.
22. Cousins MS, Stamat HM, de Wit H. 2001. Acute doses of d-amphetamine and bupropion increase cigarette smoking. Psychopharmacology 157: 243-253.
23. Crooks PA, Li M, Dwoskin LP. 1997. Metabolites of nicotine in rat brain after peripheral nicotine administration-Cotinine, nornicotine, and norcotinine. Drug Metabolism Disposition 25: 47-54.
24. Di Matteo V, Pierucci M, Di Giovanni G, Benigno A, Esposito E. 2007. The neurobiological bases for the pharmacotherapy of nicotine addiction. Current Pharma Des 13: 1269-1284.
25. Dichiara G, Imperato A. 1988. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 85: 5274-5278.
26. Drew AE, Derbez AE, Werling LL. 2000. Nicotinic receptor-mediated regulation of dopamine transporter activity in rat prefrontal cortex. Synapse 38: 10-16.
27. Drew AE, Werling LL. 2001. Protein kinase C regulation of dopamine transporter initiated by nicotinic receptor activation in slices of rat prefrontal cortex. J Neurochem 77: 839-848.
28. Drew AE, Werling LL. 2003. Nicotinic receptor-mediated regulation of the dopamine transporter in rat prefrontocortical slices following chronic in vivo administration of nicotine. Schizophrenia Res 65: 47-55.
29. Dwoskin LP, Teng LH, Crooks PA. 2001. Nornicotine, a nicotine metabolite and tobacco alkaloid: Desensitization of nicotinic receptor-stimulated dopamine release from rat striatum. Eur J Pharmacol 428: 69-79.
30. Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT. 2006. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev 12(3-4): 178-207.
31. Fagerstrom K. 2002. The epidemiology of smoking-Health consequences and benefits of cessation. Drugs 62: 1-9.
32. Ferrari R, Le Novere N, Picciotto MR, Changeux JP, Zoli M. 2002. Acute and long-term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections. Eur J Neurosci 15: 1810-1818.
33. Fletcher PJ, Le AD, Higgins GA. 2008. Serotonin receptors as potential targets for modulation of nicotine use and dependence. Serotonin-Dopamine Interaction: Experimental Evidence and Therapeutic Relevance. Progress in Brain Research 172: 361-383.
34. Fowles J, Dybing E. 2003. Application of toxicological risk assessment principles to the Chem constituents of cigarette smoke. Tobacco Control 12: 424-430.
35. Gainetdinov RR, Caron MG. 2003. Monoamine transporters: From genes to behavior. Annu Rev Pharmacol Toxicol 43: 261-284.
36. Franke B, Hoogman M, Vasquez AA, Heister J, Savelkoul PJ, Naber M, Scheffer H, Kiemeney LA, Kan CC, Kooij JJS, Buitelaar JK. 2008. Association of the dopamine transporter (SLC6A3/DAT1) gene 9-6 haplotype with adult ADHD. Am J Med Gene Part B-Neuropsychiatric Gene 147: 1576-1579.
37. Gerra G, Garofano L, Zaimovic A, Moi G, Branchi B, Bussandri M, Brambilla F, Donnini C. 2005. Association of the serotonin transporter promoter polymorphism with smoking behavior among adolescents. Am J Med Gene Part B-Neuropsychiatric Gene 135: 73-78.
38. Gray KM, Upadhyaya HP. 2009. Tobacco smoking in individuals with attention-deficit hyperactivity disorder epidemiology and pharmacological approaches to cessation. Cns Drugs 23: 661-668.
39. Green TA, Crooks PA, Bardo MT, Dwoskin LP. 2001. Contributory role for nornicotine in nicotine neuropharmacology: Nornicotine-evoked [H-3]dopamine overflow from rat nucleus accumbens slices. Biochemical Pharmacology 62: 1597-1603.
40. Gu H, Wall SC, Rudnick G. 1994. Stable expression of biogenic-amine transporters reveals differences in inhibitor sensitivity, kinetics, and ion dependence. J Biol Chem 269: 7124-7130.
41. Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A. 1999. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Int Med 159: 2033-2038.
42. Hall SM, Humfleet GL, Reus VI, Munoz RF, Hartz DT, Maude-Griffin R. 2002. Psychological intervention and antidepressant treatment in smoking cessation. Arch Gen Psychiatry 59: 930-936.
43. Hart C, Ksir C. 1996. Nicotine effects on dopamine clearance in rat nucleus accumbens. J Neurochem 66: 216-221.
44. Heal DJ, Cheetham SC, Smith SL. 2009. The neuropharmacology of ADHD drugs in vivo: Insights on efficacy and safety. Neuropharmacology 57(7-8): 608-618.
45. Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP. 1996. Allelic variation of human serotonin transporter gene expression. J Neurochem 66: 2621-2624.
46. Hoffman BJ, Hansson SR, Mezey E, Palkovits M. 1998. Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Frontiers Neuroendocrinol 19: 187-231.
47. Howell LL, Kimmel HL. 2008. Monoamine transporters and psychostimulant addiction. Biochem Pharmacol 75: 196-217.
48. Hughes JR, Stead LF, Lancaster T. 2007. Antidepressants for smoking cessation. Cochrane Database Systematic Rev 1: 77.
49. Hurt RD, Sachs DPL, Glover editors, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM. 1997. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 337: 1195-1202.
50. Ishikawa H, Ohtsuki T, Ishiguro H, Yamakawa-Kobayashi K, Endo K, Lin YL, Yanagi H, Tsuchiya S, Kawata K, Hamaguchi H, Arinami T. 1999. Association between serotonin transporter gene polymorphism and smoking among Japanese males. Cancer Epidemiol Biomarkers Prev 8: 831-833.
51. Izenwasser S, Cox BM. 1992. Inhibition of dopamine uptake by cocaine and nicotine-Tolerance to chronic treatments. Brain Res 573: 119-125.
52. Itoh H, Toyohira Y, Ueno S, Saeki S, Zhang H, Furuno Y, Takahashi K, Tsutsui M, Hachisuka K, Yanagihara N. 2010. Upregulation of norepinephrine transporter function by prolonged exposure to nicotine in cultured bovine adrenal medullary cells. Naunyn-Schmiedebergs Arch Pharmacol 382: 235-243.
53. Izenwasser S, Jacocks HM, Rosenberger JG, Cox BM. 1991. Nicotine indirectly inhibits [H-3] dopamine uptake at concentrations that do not directly promote [H-3] dopamine release in rat striatum. J Neurochem 56: 603-610.
54. Jorenby DE. 2006. Efficacy of varenicline, an alpha 4 beta 2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial (vol 296, pg 56, 2006). J Am Med Assoc 296: 1355-1355.
55. Joung Y, Kim CH, Moon J, Jang WS, Yang J, Shin D, Lee S, Kim KS. 2009. Association studies of-3081(A/T) polymorphism of norepinephrine transporter gene with attention deficit/hyperactivity disorder in korean population. Am J Med Gene Part B-Neuropsychiatric Gene 153: 691-694.
56. Jutkiewicz EM, Nicolazzo DM, Kim MN, Gnegy ME. 2008. Nicotine and amphetamine acutely cross-potentiate their behavioral and neurochemical responses in female Holtzman rats. Psychopharmacology 200: 93-103.
57. Kalman D, Morissette SB, George TP. 2005. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am J Addict 14: 106-123.
58. Kang AM, Palmatier MA, Kidd KK. 1999. Global variation of a 40-bp VNTR in the 3'-untranslated region of the dopamine transporter gene (SLC6A3). Biol Psychiatry 46: 151-160.
59. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K, Ackenheil M. 2002. Stimulant-like action of nicotine on striatal dopamine transporter in the brain of adults with attention deficit hyperactivity disorder. Int J Neuropsychopharmacol 5: 111-113.
60. Lasser K, Boyd JW, Woolhandler S, Himmelstein DU, McCormick D, Bor DH. 2000. Smoking and mental illness-A population-based prevalence study. JAMA 284: 2606-2610.
61. Laucht M, Becker K, Frank J, Schmidt MH, Esser G, Treutlein J, Skowronek MH, Schumann G. 2008. Genetic variation in dopamine pathways differentially associated with smoking progression in adolescence. J Am Acad Child Adolesc Psychiatr 47: 673-681.
62. Lerman C, Caporaso NE, Audrain J, Main D, Bowman editors, Lockshin B, Boyd NR, Shields PG. 1999. Evidence suggesting the role of specific genetic factors in cigarette smoking. Health Psychol 18: 14-20.
63. Leroy C, Bragulat V, Berlin I, Gregoire MC, Bottlaender M, Roumenov D, Dolle F, Bourgeois S, Penttila J, Artiges E, Martinot JL, Trichard C. 2009. Cerebral monoamine oxidase a inhibition in tobacco smokers confirmed with PET and [C-11]Befloxatone. J Clin Psychopharmacol 29: 86-88.
64. Lewis A, Miller JH, Lea RA. 2007. Monoamine oxidase and tobacco dependence. Neurotoxicology 28: 182-195.
65. Li LB, Chen NH, Ramamoorthy S, Chi LM, Cui XN, Wang LJC, Reith MEA. 2004a. The role of N-glycosylation in function and surface trafficking of the human dopamine transporter. J Biol Chem 279: 21012-21020.
66. Li MD, Ma JZ, Beuten J. 2004b. Progress in searching for susceptibility loci and genes for smoking-related behaviour. Clin Gene 66: 382-392.
67. Li SP, Kim KY, Kim JH, Kim JH, Park MS, Bahk JY, Kim MO. 2004c. Chronic nicotine and smoking treatment increases dopamine transporter mRNA expression in the rat midbrain. Neurosci Lett 363: 29-32.
68. Ling DJ, Niu TH, Feng Y, Xing HX, Xu XP. 2004. Association between polymorphism of the dopamine transporter gene and early smoking onset: An interaction risk on nicotine dependence. J Hum Genet 49: 35-39.
69. Ma Z, Strecker RE, McKenna JT, Thakkar MM, McCarley RW, Tao R. 2005. Effects on serotonin of (-)nicotine and dimethylphenylpiperazinium in the dorsal raphe and nucleus accumbens of freely behaving rats. Neuroscience 135: 949-958.
70. Melikian HE. 2004. Neurotransmitter transporter trafficking: endocytosis, recycling, and regulation. Pharmacol Therapeutics 104: 17-27.
71. Middleton LS, Cass WA, Dwoskin LP. 2004. Nicotinic receptor modulation of dopamine transporter function in rat striatum and medial prefrontal cortex. J Pharmacol Exp Therapeutics 308: 367-377.
72. Middleton LS, Apparsundarain S, King-Pospisil KA, Dwoskin LP. 2007a. Nicotine increases dopamine transporter function in rat striatum through a trafficking-independent mechanism. Eur J Pharmacol 554(2-3): 128-136.
73. Middleton LS, Crooks PA, Wedlund PJ, Cass WA, Dwoskin LP. 2007b. Nornicotine inhibition of dopamine transporter function in striatum via nicotinic receptor activation. Synapse 61: 157-165.
74. Miller DK, Wong EHF, Chesnut MD, Dwoskin LP. 2002. Reboxetine: Functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. J Pharmacol Exp Therapeutics 302: 687-695.
75. Miller LR, Mukherjee S, Ansah TA, Das SK. 2007. Cigarette smoke and dopaminergic system. J Biochem Mol Toxicol 21: 325-335.
76. Murphy DL, Lerner A, Rudnick G, Lesch KP. 2004. Serotonin transporter: Gene, genetic disorders, and pharmacogenetics. Mol Interv 4: 109-123.
77. Newberg A, Lerman C, Wintering N, Ploessl K, Mozley PD. 2007. Dopamine transporter binding in smokers and nonsmokers. Clin Nuclear Med 32: 452-455.
78. Nisell M, Nomikos GG, Hertel P, Panagis G, Svenssom TH. 1996. Condition-independent sensitization of locomotor stimulation and mesocortical dopamine release following chronic nicotine treatment in the rat. Synapse 22: 369-381.
79. Ohyama K, Sogawa C, Sogawa N, Morita K, Dohi T, Kitayama S. 2010. Nicotine stimulates transcriptional activity of the human dopamine transporter gene. Neurosci Lett 471: 34-37.
80. Paterson NE, Balfour DJ, Markou A. 2007. Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur J Neurosci 25: 3099-3108.
81. Paterson NE. 2009. Behavioural and pharmacological mechanisms of bupropion's anti-smoking effects: Recent preclinical and clinical insights. Eur J Pharmacol 603(1-3): 1-11.
82. Paterson NE, Semenova S, Markou A. 2008. The effects of chronic versus acute desipramine on nicotine withdrawal and nicotine self-administration in the rat. Psychopharmacology 198: 351-362.
83. Pierce RC, Kumaresan V. 2006. The mesolimbic dopamine system: The final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 30: 215-238.
84. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D. 1998. A randomized trial of nortriptyline for smoking cessation. Arch Internal Med 158: 2035-2039.
85. Rahman S, Zhang J, Corrigall WA. 2003. Effects of acute and chronic nicotine on somatodendritic dopamine release of the rat ventral tegmental area: In vivo microdialysis study. Neurosci Lett 348: 61-64.
86. Rauhut AS, Mullins SN, Dwoskin LP, Bardo MT. 2002. Reboxetine: Attenuation of intravenous nicotine self-administration in rats. J Pharmacol Exp Therapeutics 303: 664-672.
87. Rossi S, Singer S, Shearman E, Sershen H, Lajtha A. 2005. Regional heterogeneity of nicotine effects on neurotransmitters in rat brains in vivo at low doses. Neurochem Res 30: 91-103.
88. Rush CR, Higgins ST, Vansickel AR, Stoops WW, Lile JA, Glaser PEA. 2005. Methylphenidate increases cigarette smoking. Psychopharmacology 181: 781-789.
89. Schmid B, Blomeyer D, Becker K, Treutlein J, Zimmermann US, Buchmann AF, Schmidt MH, Esser G, Banaschewski T, Rietschel M, Laucht M. 2009. The interaction between the dopamine transporter gene and age at onset in relation to tobacco and alcohol use among 19-year-olds. Addict Biol 14: 489-499.
90. Scholze P, Orr-Urtreger A, Changeux JP, McIntosh JM, Huck S. 2007. Catecholamine outflow from mouse and rat brain slice preparations evoked by nicotinic acetylcholine receptor activation and electrical field stimulation. Br J Pharmacol 151: 414-422.
91. Semba J, Wakuta M. 2008. Chronic effect of nicotine on serotonin transporter mRNA in the raphe nucleus of rats: Reversal by co-administration of bupropion. Psychiatry Clin Neurosci 62: 435-441.
92. Sieminska A, Buczkowski K, Jassem E, Niedoszytko M, Tkacz E. 2009. Influences of polymorphic variants of DRD2 and SLC6A3 genes, and their combinations on smoking in Polish population. BMC Med Genet 10: 92.
93. Singer S, Rossi S, Verzosa S, Hashim A, Lonow R, Cooper T, Sershen H, Lajtha A. 2004. Nicotine-induced changes in neurotransmitter levels in brain areas associated with cognitive function. Neurochem Res 29: 1779-1792.
94. Sofuoglu M, Sewell RA. 2009. Norepinephrine and stimulant addiction. Addict Biol 14: 119-129.
95. Stedman RL. 1968. Chem composition of tobacco and tobacco smoke. Chem Rev 68: 153-&.
96. Tidey JW, O'Neill SC, Higgins ST. 2000. d-Amphetamine increases choice of cigarette smoking over monetary reinforcement. Psychopharmacology 153: 85-92.
97. Torres GE, Gainetdinov RR, Caron MG. 2003. Plasma membrane monoamine transporters: Structure, regulation and function. Nat Rev Neurosci 4: 13-25.
98. Vansickel AR, Poole MM, Stoops WW, Hays KE, Upchurch MB, Glaser PEA, Rush CR. 2009. Stimulant-induced changes in smoking and caloric intake: Influence of rate of onset. Pharmacol Biochem Behav 92: 597-602.
99. Vansickel AR, Stoops WW, Glaser PEA, Rush CR. 2007. A pharmacological analysis of stimulant-induced increases in smoking. Psychopharmacology 193: 305-313.
100. Weinshenker D, Schroeder JP. 2007. There and back again: A tale of norepinephrine and drug addiction. Neuropsychopharmacology 32: 1433-1451.
101. W.H.O. 2006. The facts about smoking and health.: World Health Organisation.
102. Wooters TE, Neugebauer NM, Rush CR, Bardo MT. 2008. Methylphenidate enhances the abuse-related behavioral effects of nicotine in rats: Intravenous self-administration, drug discrimination, and locomotor cross-sensitization. Neuropsychopharmacology 33: 1137-1148.
103. Yamashita H, Kitayama S, Zhang YX, Takahashi T, Dohi T, Nakamura S. 1995. Effect of nicotine on dopamine uptake in COS cells possessing the rat dopamine transporter and PC12 cells. Biochem Pharmacol 49: 742-745.
104. Yang YK, Yao WJ, Yeh TL, Lee IH, Chen PS, Lu RB, Chiu NT. 2008. Decreased dopamine transporter availability in male smokers - A dual isotope SPECT study. Prog Neuro-Psychopharmacol Biol Psychiatry 32: 274-279.
105. Zhu CB, Hewlett WA, Feoktistov I, Biaggioni I, Blakely RD. 2004. Adenosine receptor, protein kinase G and p38 mitogen-activated protein kinase-dependent up-regulation of serotonin transporters involves both transporter trafficking and activation. Mol Pharmacol 65: 1462-1474.
106. Zhu J, Apparsundaram S, Dwoskin LP. 2009. Nicotinic receptor activation increases [H-3]dopamine uptake and cell surface expression of dopamine transporters in rat prefrontal cortex. J Pharmacol Exp Therapeutics 328: 931-939.